"Il Pascale è il maggiore IRCCS Oncologico del Mezzogiorno ed è Centro di Riferimento per la rete oncologica nazionale e regionale. L'Istituto persegue finalità di ricerca prevalentemente clinica, e di ricerca applicata nel campo biomedico e in quello dell'organizzazione e gestione dei servizi sanitari, dedicando grande impegno alle problematiche più ampie del paziente oncologico, che vanno dall'assistenza psicologica ai problemi nutrizionali, alla terapia del dolore, alle cure palliative in genere, fino alle fasi più delicate della malattia."

During the past decade, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale" conducted 243 clinical trials. In the 10-year time frame, 243 clinical trials started and 88 clinical trials were completed, i.e. on average, 36.2% percent of trials that started reached the finish line to date. In the past 5 years, 114 clinical trials started and 62 clinical trials were completed. i.e. 54.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale"" #1 sponsor was "Hoffmann-La Roche" with 66 trials, followed by "National Cancer Institute, Naples" with 48 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 19 trials sponsored, "Bristol-Myers Squibb" with 13 trials sponsored and "Celgene" with 13 trials sponsored. Other sponsors include 197 different institutions and companies that sponsored additional 107 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale"" #1 collaborator was "Merck Sharp & Dohme LLC" with 11 trials as a collaborator, "Clinical Research Technology S.r.l." with 8 trials as a collaborator, "AstraZeneca" with 4 trials as a collaborator, "Bristol-Myers Squibb" with 4 trials as a collaborator and "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 4 trials as a collaborator. Other collaborators include 136 different institutions and companies that were collaborators in the rest 116 trials.

According to Clinical.Site data, the most researched conditions in "Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale"" are "Breast Cancer" (24 trials), "Ovarian Cancer" (24 trials), "Melanoma" (19 trials), "Metastatic Breast Cancer" (13 trials) and "Colorectal Cancer" (12 trials). Many other conditions were trialed in "Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale"" in a lesser frequency.

Most popular intervention types in "Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale"" are "Drug" (300 trials), "Biological" (27 trials), "Procedure" (27 trials), "Other" (19 trials) and "Radiation" (8 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (35 trials), "Atezolizumab" (29 trials), "Paclitaxel" (27 trials), "Carboplatin" (21 trials) and "Bevacizumab" (19 trials). Other intervention names were less common.

The vast majority of trials in "Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale"" are 289 trials for "All" genders, 64 trials for "Female" genders and 8 trials for "Male" genders.

Currently, there are NaN active trials in "Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale"". undefined are not yet recruiting, 85 are recruiting, 98 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 111 completed trials in Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", 1 suspended trials, and 28 terminated clinical trials to date.

Out of the total trials that were conducted in Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", 49 "Phase 1" clinical trials were conducted, 144 "Phase 2" clinical trials and 152 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 11 trials that are defined as “Not Applicable".

Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale" has several departments that took part in Clinical trials: "ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico" - 11 trials, "National Cancer Institute - IRCCS "Fondazione G. Pascale"" - 5 trials, "IRCCS IST. Tumori Fondaz. Pascale; S.C. Oncologia Medica,Melanoma,Immunoterapia E Terapie Innovative" - 3 trials, "Unita Sperimentazioni Cliniche Istituto per lo" - 3 trials, "U.O.S.C Di Oncologia Medica E Terapie Innovative" - 2 trials